Bristol-Myers Squibb Price Target Raised to $72, Pipeline Success Odds Hit 90%
Guggenheim raised its price target on Bristol-Myers Squibb to $72 from $62 on February 6 and lifted success odds for iber/mezi to 90% from 33% and for milvexian in SSP to 90% from 75%. Bristol-Myers Squibb reported fourth-quarter revenue of $12.5 billion, topping the $12.28 billion consensus.
1. Guggenheim Boosts Price Target and Odds
On February 6, Guggenheim raised its Bristol-Myers Squibb price target to $72 from $62 and reiterated a Buy rating. The firm increased its estimated probability of success for the iber/mezi oncology asset to 90% from 33% and for milvexian in SSP to 90% from 75%.
2. Peer Upgrades Follow Strong Results
Bank of America lifted its price target to $68 from $64 while maintaining a Buy rating, citing robust Q4 results and pipeline strength. Wells Fargo raised its target to $60 with an Equal Weight rating, and Citi increased its target to $64, emphasizing solid fourth-quarter performance and upcoming clinical readouts.
3. Q4 Financial Beat and Outlook
Bristol-Myers Squibb reported fourth-quarter revenue of $12.5 billion, exceeding the $12.28 billion consensus and reinforcing confidence in its growth portfolio. Executive commentary highlighted a strengthened balance sheet and a data-rich 2026 with several pivotal Phase 3 catalysts expected in the back half of the year.